Boehringer Ingelheim plans sustainability work for the long term
Boehringer Ingelheim’s For Generations framework is all in on sustainability for the long term across the ESG spectrum.
12 July 2024
12 July 2024
Boehringer Ingelheim’s For Generations framework is all in on sustainability for the long term across the ESG spectrum.
J&J gains Phase II ready NM26, a bispecific antibody in development for the treatment of atopic dermatitis.
The company did not expect to resolve concerns related to manufacturing and the safety profile for type 1 diabetes by the end of the year.
FS001 targets a novel antigen prevalent in many solid tumours and critical for their growth.
AB-1005 is an investigational adeno-associated virus 2 glial cell line-derived neurotrophic factor (AAV2-GDNF) neurorestorative gene therapy.
The deal strengthens Merz’s market position in Parkinson’s disease while expanding into the multiple sclerosis sector.
Novo Nordisk-partnered Aspect develops bio-printed tissue therapeutics designed to replace or support specific biological functions.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.